Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial
Open Access
- 11 October 2021
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 16 (1) , 1-10
Abstract
Background: Propionic acidemia (PA) and methylmalonic acidemia (MMA) are rare, autosomal recessive inborn errors of metabolism that require life-long medical treatment. The trial aimed to evaluate the effectiveness of the administration of carglumic acid with the standard treatment compared to the standard treatment alone in the management of these organic acidemias. Methods: The study was a prospective, multicenter, randomized, parallel-group, open-label, controlled clinical trial. Patients aged ≤ 15 years with confirmed PA and MMA were included in the study. Patients were followed up for two years. The primary outcome was the number of emergency room (ER) admissions because of hyperammonemia. Secondary outcomes included plasma ammonia levels over time, time to the first episode of hyperammonemia, biomarkers, and differences in the duration of hospital stay. Results: Thirty-eight patients were included in the study. On the primary efficacy endpoint, a mean of 6.31 ER admissions was observed for the carglumic acid arm, compared with 12.76 for standard treatment, with a significant difference between the groups (p = 0.0095). Of the secondary outcomes, the only significant differences were in glycine and free carnitine levels. Conclusion: Using carglumic acid in addition to standard treatment over the long term significantly reduces the number of ER admissions because of hyperammonemia in patients with PA and MMA.Keywords
Funding Information
- King Abdullah International Medical Research Center (RC13/116)
- King Fahad Medical City (14-165)
This publication has 30 references indexed in Scilit:
- Acute management of propionic acidemiaMolecular Genetics and Metabolism, 2012
- N-carbamylglutamate Augments Ureagenesis and Reduces Ammonia and Glutamine in Propionic AcidemiaPediatrics, 2010
- Effects of a single dose of N-carbamylglutamate on the rate of ureagenesisMolecular Genetics and Metabolism, 2009
- N-Carbamylglutamate in Emergency Management of Hyperammonemia in Neonatal Acute Onset Propionic and Methylmalonic AciduriaNeonatology, 2009
- Using Regression Models to Analyze Randomized Trials: Asymptotically Valid Hypothesis Tests Despite Incorrectly Specified ModelsBiometrics, 2009
- N‐Carbamylglutamate for neonatal hyperammonaemia in propionic acidaemiaJournal of Inherited Metabolic Disease, 2008
- Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia?Orphanet Journal of Rare Diseases, 2008
- Methylmalonic and propionic acidaemias: Management and outcomeJournal of Inherited Metabolic Disease, 2005
- N‐Carbamylglutamate protects patients with decompensated propionicaciduria from hyperammonaemiaJournal of Inherited Metabolic Disease, 2005
- Sample size for Poisson regressionBiometrika, 1991